Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Ruxolitinib in Patients With Head and Neck Squamous Cell Carcinoma and High Neutrophil-to-Lymphocyte Ratio Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial

NCT07840456 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT07840456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07840456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Ruxolitinib in Patients With Head and Neck Squamous Cell Carcinoma and High Neutrophil-to-Lymphocyte Ratio Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
February 28, 2029
Enrollment
66 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell of head and neck hnscc